Koninklijke Philips (NYSE:PHG) to Issue $0.92 Annual Dividend

Koninklijke Philips (NYSE:PHG) announced an annual dividend on Wednesday, May 8th, Wall Street Journal reports. Shareholders of record on Friday, May 10th will be paid a dividend of 0.9154 per share by the technology company on Thursday, May 9th. This represents a yield of 3.5%. The ex-dividend date is Thursday, May 9th.

Koninklijke Philips Stock Performance

PHG stock traded down $0.51 during mid-day trading on Wednesday, hitting $26.00. 1,016,553 shares of the company were exchanged, compared to its average volume of 1,189,770. The stock has a market capitalization of $24.14 billion, a PE ratio of -27.61, a price-to-earnings-growth ratio of 1.39 and a beta of 0.75. The company has a current ratio of 1.20, a quick ratio of 0.78 and a debt-to-equity ratio of 0.58. Koninklijke Philips has a 1-year low of $17.75 and a 1-year high of $29.44. The business has a 50 day simple moving average of $21.35 and a 200-day simple moving average of $21.33.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the company. StockNews.com upgraded Koninklijke Philips from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 8th. UBS Group raised Koninklijke Philips from a “sell” rating to a “neutral” rating in a research note on Tuesday, April 30th. JPMorgan Chase & Co. raised shares of Koninklijke Philips from an “underweight” rating to a “neutral” rating in a report on Tuesday, April 30th. Finally, BNP Paribas raised shares of Koninklijke Philips from an “underperform” rating to a “neutral” rating in a report on Tuesday. Three investment analysts have rated the stock with a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $19.00.

About Koninklijke Philips

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.